Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan

Share:

ALK (OTC: AKABY) today announced that the sublingual allergy immunotherapy product MITICURE now will be available for prescription in Japan for adults and adolescents (12-64 years) who suffer from house dust mite allergic rhinitis.

As of today, MITICURE(tm) has been placed on the Japanese National Health Insurance reimbursement list and will be launched in the beginning of December 2015.  

MITICURE(tm) is the Japanese trade name of the sublingual allergy immunotherapy tablet licensed by ALK to Torii for Japan. MITICURE(tm) is indicated in adults and adolescents (12-64 years) for the treatment of allergic rhinitis caused by house dust mites. With the intention of obtaining approval for pediatric use (5-11 years), Torii is currently conducting a Phase III clinical trial involving approximately 400 patients. 

Torii has issued a news release concerning the launch of MITICURE(tm) which can be found on http://www.torii.co.jp. 

The product was recently approved in 11 European countries where it is expected to soon become available in the first markets under the trade name ACARIZAX(r) for the treatment of house dust mite allergic rhinitis and allergic asthma in adults (18-65 years). 

The product is also being developed for a number

See full press release

Posted-In: News Press Releases

 

Related Articles (MRK + AKABY)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Tesla Opens Basel, Switzerland Store on St.-Alban-Graben

Jon Najarian Is Bullish On Yahoo